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Schizophrenia remains one of the most devastating chronic
illnesses,1 impacting nearly 1.5% of the global population2 and
creating an economic burden of up to 1.65% gross domestic
product.3 It is not surprising that digital tools for schizophrenia,
often smartphone-based software in the form of apps, have
received so much recent attention and enthusiasm. Digital
phenotyping holds tremendous potential in elucidating the
complex heterogeneity of what we call schizophrenia and would
therefore advance research. On a clinical front, smartphone data
may become increasingly valuable in monitoring course and
treatment response given the fact that these patients frequently
have difﬁculties in adherence with clinical visits, and are often
poor historians. However, the power of this paradigm is currently
fueled more by the increasing ubiquity of technology than
breakthroughs in clinical science. The accessibility and afford-
ability of digital care derives from increasing global ownership of
smartphones: it is estimated that six billion smartphones will be in
circulation worldwide by 2020.4 As devices and sensors become
ever cheaper and more sophisticated, the ability to capture a
plethora of relevant data and deliver a myriad of content via
network connectivity will continue to fuel the potential of digital
approaches in mental health. As validation and reproducibility lags
behind enthusiasm and availability, the potential clinical impact of
these digital tools is at a crossroads.
How might this new approach advance clinical care? Affordable
and accurate diagnostics from smartphones paired with on-
demand or automatically deployed interventions enables unpre-
cedented access to mental health services. Apps today are
designed to perform a wide range of healthcare tasks ranging
from telehealth to medication tracking. In addition, new platforms
are currently being developed to measure novel behavioral and
physiological markers using passive long-term smartphone data,
enabling objective measurement without burden for patients and
healthcare providers. Clinically relevant and passively collected
smartphone data comprises a wide range of sensors, including
accelerometer data to estimate activity, anonymized call/text log
information to estimate sociability, and screen touch data to
estimate cognition. Passive measurement might also be able to
distinguish disease subtypes to help better classify psychotic
illnesses, similar to recent research using genetic, physiological,
and cognitive markers.5
The considerable potential impact of these tools is paralleled by
substantial new challenges. Formidable analytical complexities
accompany all data-driven approaches, including clinical inference
using passive smartphone data. Missing data, the high-
dimensional and temporally dense nature of the collected data,
habits of smartphone use, quality of user experience with the app,
and the quality of the software implementation may all act as
confounders to underlying clinical disease state. Estimates of
clinical accuracy and efﬁcacy of these devices remains broadly
understudied. Daunting implementation challenges also
accompany this smartphone-based work: simple questions such
as which patients are comfortable with smartphone monitoring,
how long should it be used for, how information should be shared
with patients and psychiatrists all remain largely unknown. Ethical
questions also remain with respect to appropriate storage, access,
and usage protocols for this highly personal data.6
Ignoring these challenges and questions would be both a
scientiﬁc mistake and also a missed opportunity for clinical care.
Recall the humorous 2009 case report of the dead North Atlantic
Salmon, who was asked to detect emotions in photos during a
fMRI task, resulting in the “ﬁnding” of correlated neural activity—
due to failing to control for multiple comparisons.7 Online
analyses of digital phenotyping data performed on say, a daily
basis, are faced with the same challenge of correcting for multiple
comparisons. The more recent discovery of widespread statistical
software issues in thousands of fMRI research protocols under-
scores how simple mistakes can be ampliﬁed with digital tools.8
The promise of fMRI is owed to its high-resolution detail, which is
directly tied to data complexity and the peril of inappropriate
statistical inference. Digital phenotyping9 data, which is in situ,
multi-sensor, partially observed, and longitudinal, brings even
more complexity to bear, and deserves proportionate
circumspection.
To meet these challenges and to hone this approach into
clinically useful tools, the development of research platforms must
be accompanied with empirical research on the properties of the
data it collects, called metadata. A simple example of metadata is
the time it may take you respond to a smartphone query, instead
of the response to the query itself. Studying metadata is useful for
two reasons. First, understanding the limitations and biases of our
tools used to draw clinical inferences will improve their speciﬁcity
and clarify where they can be beneﬁcially used. Second, metadata
itself might offer novel insights about patient behavior and
especially cognition that is not available using traditional metrics
or evaluations. Recent research from our group10 suggests that
properties of smartphone data may be more complex than often
portrayed in the popular press, which holds relevance for clinical
use. We show a correlation in the outcomes between metadata
such as accelerometer coverage, GPS coverage, and survey
completion timings, and future responses to questions about
mood, anxiety, and psychotic symptoms. This might be evidence
that these measures might help predict disease progression. We
also ﬁnd that some of these measures differ by operating system
(iOS vs. Android), potentially indicating confounding by operating
system or other variables, such as socioeconomic status.
In addition to understanding metadata, the development of
digital phenotyping tools will beneﬁt from other considerations.
Data standards and extensive testing may take signiﬁcant
forethought and precious resources, but such care typically helps
the success of deployment in the long run. Without standards in
collecting, processing, and reporting for digital phenotyping data,
the end result might be a continuation of the pilot studies we
currently see, which are expensive and their results are often left
unreplicated. This pales in comparison to the value of high-
throughput, well-coordinated, multi-site research efforts seen in
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ﬁelds such as genetics and molecular life sciences. As digital tools
are built with the apparent goal of providing and complementing
current care, choices made now will reﬂect on the replicability and
effectiveness of these tools once widely deployed.
Although the digital phenotyping approach requires extensive
validation, embracing the complexity of tools now, including a
thorough understanding of clinical metadata, will enable new
ways to understand mental illnesses and deliver personalized
medicine for schizophrenia and related disorders.11 At the
crossroads of validation and reproducibility versus enthusiasm
and availability lies the challenge to bridge both sides and realize
the full potential of these new digital tools.
The crossroads of the ﬁeld presents a choice of path along
which this important ﬁeld will develop.
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